PALI
Palisade Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.09
+2.20%Next report
Analyst consensus
- Next report date
- Nov 9, 2026
- EPS estimate
- -$0.06
- Revenue estimate
- $465.3K
Latest reported
- Last report date
- Aug 10, 2026
- EPS actual
- -$0.05
- EPS estimate
- -$0.05
- Revenue actual
- $500.0K
- Revenue estimate
- $500.0K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 7
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -13.9%
- Revenue beats (12Q)
- 0
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 9, 2026